Please login to the form below

Not currently logged in
Email:
Password:

eosinophilic

This page shows the latest eosinophilic news and features for those working in and with pharma, biotech and healthcare.

AZ gets EMA green light for severe asthma drug Fasenra

AZ gets EMA green light for severe asthma drug Fasenra

The new drug has been given a green light by the EMA as an add-on maintenance treatment for severe eosinophilic asthma in patients who can’t control symptoms using ... Many patients with severe eosinophilic asthma experience debilitating symptoms and

Latest news

  • GSK gets another approval for Nucala in US GSK gets another approval for Nucala in US

    The US regulator gave the go-ahead yesterday to use Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, inflammation in ... Nucala has been approved

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    The US regulator has approved the drug as an add-on treatment for severe eosinophilic asthma in patients over 12. ... The eosinophilic form is seen in about half of all severe asthma patients and is associated with worse symptoms, decreased lung function

  • AZ severe asthma drug benralizumab backed by CHMP AZ severe asthma drug benralizumab backed by CHMP

    AZ severe asthma drug benralizumab backed by CHMP. The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma. ... The Committee for Medicinal Products for Human Use (CHMP) backed approval of benralizumab at its committee meeting

  • Sanofi, Regeneron claim EU approval for eczema drug Dupixent Sanofi, Regeneron claim EU approval for eczema drug Dupixent

    A phase III trial of the antibody in persistent, uncontrolled asthma met its targets of reducing the frequency of severe asthma attacks in patients with high levels of eosinophilic cells, setting

  • GSK preps COPD filing for asthma pioneer Nucala GSK preps COPD filing for asthma pioneer Nucala

    with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disorder characterised by widespread inflammation in the walls of small blood vessels.

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - develop and commercialise. 265. Meritage Pharma/ Shire. Phase 3-ready oral budesonide suspension (OBS) - eosinophilic esophagitis (EoE).

  • Pharma deals during March 2013 Pharma deals during March 2013

    Receptos will conduct a phase II proof-of-concept study in Eosinophilic Esophagitis, an orphan indication in the US.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics